In this week’s Pharma Pulse, the launch of the Ember Cube 2, exclusive policy insights from Asembia AXS26, a record-breaking ...
CoverMyMeds' Miranda Delatore and Megan Wetzel discuss AI in prior auth and fixing specialty access bottlenecks upstream. In ...
Scaling from ultra-rare volumes to mainstream indications threatens redundancy-heavy manufacturing and logistics, forcing redesign of distribution workflows to maintain chain-of-custody, integrity, ...
Will Shrank, MD, evaluates opportunities and challenges in specialty pharma over the next few years. In his interview with ...
At Asembia AXS26, Dee Chaudhary broke down how shifting US drug pricing policy is tightening payer controls and changing ...
Live from Asembia AXS26, Jessica Lovett explains what real world evidence and data matters most in making decisions around ...
Live from Asembia AXS26, Jessica Lovett explains what real world evidence and data matters most in making decisions around specialty medicines.
PBM reform is accelerating via FTC settlements and CAA 2026, mandating data reporting, rebate pass-through in Part D, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results